Skip to main content
AL

Avantia Labs, Inc.

This company provides bioanalytical services, including PK, immunogenicity, and biomarker analysis, to support the development of biotherapeutics. They offer cell-based assays, PCR, and real-time PCR services, enabling pharmaceutical and biotech companies to advance biological drug development with accurate data and regulatory compliance.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Biopharmaceutical companies require precise and reliable bioanalytical services to support the development of large molecule therapeutics, but outsourcing these services can be challenging due to the need for specialized expertise and regulatory compliance. Inaccurate or unreliable bioanalytical data can lead to delays in drug development and potential regulatory issues.

Solution

Avantia Labs is a contract research organization (CRO) specializing in large molecule bioanalysis, providing comprehensive services to accelerate biotherapeutic development. They offer a range of bioanalytical assays, including pharmacokinetics (PK), toxicokinetics (TK), immunogenicity, and biomarker analysis, supporting biologics development from discovery through clinical phases. Avantia Labs utilizes various technology platforms, such as ELISA, ECLIA, and qPCR, and operates under GDP, GLP, and GCP compliance to ensure data integrity and regulatory adherence. Their services include method development, method transfer, customization of commercial kits, method validation, and sample analysis.

Target Audience

Avantia Labs primarily serves pharmaceutical and biotech companies involved in the development of biotherapeutic drug modalities, including peptides, enzymes, proteins, antibodies, and gene therapeutics.

Features

  • Pharmacokinetic (PK) and toxicokinetic (TK) analysis of biologics, including monoclonal antibodies, proteins, peptides, and enzymes
  • Immunogenicity assessment, including anti-drug antibody (ADA), neutralizing antibody (Nab) assays (cell-based and binding), domain specificity, and isotype detection
  • Fit-for-purpose biomarker assay development, including de novo methods, commercial kit adaptation, and multiplexing
  • Discovery research support, including in vitro biochemistry and binding assays, enzymatic assays, and cell-based functional assays
  • Biorepository services for short- and long-term storage of samples and critical reagents under controlled conditions
  • Method validation and sample analysis under GDP, GLP, and GCP compliance
  • Utilization of platforms such as Biotek Synergy H1 Multimode Reader (ELISA), Meso Scale Discovery Sector S600 (ECLIA), and Quant Studio 7 Pro Real Time PCR System (qPCR)
  • Comprehensive data management and reporting procedures to ensure data reliability, reproducibility, and compliance
This profile is AI-generated and may contain inaccuracies.